Junki Koike
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Junki Koike has a total of 264 co-authors. Here are the top co-authors by number of shared publications:
- Masayoshi Okumi
Department of Urology Kyoto Prefectural University of Medicine Kyoto Japan
5 shared publications Shigeru Horita
Division of Clinical Pathology, Kidney Center Tokyo Women's Medical University Tokyo Japan
5 shared publications- Yoji Nagashima
Department of Surgical Pathology Tokyo Women's Medical University Shinjuku‐ku Tokyo Japan
5 shared publications - Hiroaki Kitagawa
Department of Pediatric Surgery, St. Marianna University School of Medicine, Kawasaki, Japan
4 shared publications - Hisashi Saji
Department of Thoracic Surgery, St. Marianna University School of Medicine, Kawasaki, Japan
4 shared publications - Kanji Otsubo
Thoracic Surgery, St. Marianna University School of Medicine, Kawasaki, Japan, Kanagawa, Japan, Japan
4 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Wiley in Thoracic Cancer
- Vol. 17 (20) , e70400
Clinicopathological Features of DLL3 Expression and T‐Cell Infiltration in LCNEC : Insights From Pathology and Clinical Response to Tarlatamab
Background: Large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive lung neuroendocrine neoplasm with poor prognosis. Recently, DLL3‐targeted bispecific T‐cell engagers (BiTEs) have shown promising efficacy in small cell lung cancer, and clinical trials are ongoing in LCNEC. This study evaluated DLL3 expression and CD8+ tumor‐infiltrating lymphocytes (TILs) infiltration in LCNEC and investigated their clinical significance and association with tarlatamab efficacy. Methods: We retrospectively reviewed consecutive patients who were diagnosed with LCNEC. Immunohistochemical analyses for DLL3 and CD8 were performed. DLL3 positivity was defined as staining in ≥ 1% of tumor cells. CD8+ TIL infiltration was graded as low, moderate, or high. Results: Among 77 screened LCNEC cases, 44 were eligible for analysis. The median age was 75 years. DLL3 expression was observed in 70.5% of cases and was associated with worse survival. Low CD8+ TIL infiltration was observed in 59.1% of cases. Patients with high CD8+ TIL infiltration demonstrated significantly longer survival than those with low infiltration ( p = 0.03). Among representative clinical cases, a patient with DLL3 (+)/CD8 TILs (−) LCNEC achieved marked tumor shrinkage, whereas a patient with DLL3 (−)/CD8 TILs (−) LCNEC showed no response. Conclusions: DLL3 is frequently expressed in LCNEC and correlates with a poorer prognosis. A majority of LCNEC cases are immunologically characterized as cold tumors lacking CD8+ TILs, which contributes to unfavorable clinical outcomes. Tarlatamab induced a robust antitumor response even in a DLL3 (+) cold tumor. DLL3‐BiTE represents a promising therapeutic strategy for DLL3 (+) LCNEC.
- 15 October 2026
- Published by Wiley in Thoracic Cancer
- Vol. 17 (20) , e70400
Open AccessClinicopathological Features of DLL3 Expression and T‐Cell Infiltration in LCNEC : Insights From Pathology and Clinical Response to Tarlatamab
Background: Large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive lung neuroendocrine neoplasm with poor prognosis. Recently, DLL3‐targeted bispecific T‐cell engagers (BiTEs) have shown promising efficacy in small cell lung cancer, and clinical trials are ongoing in LCNEC. This study evaluated DLL3 expression and CD8+ tumor‐infiltrating lymphocytes (TILs) infiltration in LCNEC and investigated their clinical significance and association with tarlatamab efficacy. Methods: We retrospectively reviewed consecutive patients who were diagnosed with LCNEC. Immunohistochemical analyses for DLL3 and CD8 were performed. DLL3 positivity was defined as staining in ≥ 1% of tumor cells. CD8+ TIL infiltration was graded as low, moderate, or high. Results: Among 77 screened LCNEC cases, 44 were eligible for analysis. The median age was 75 years. DLL3 expression was observed in 70.5% of cases and was associated with worse survival. Low CD8+ TIL infiltration was observed in 59.1% of cases. Patients with high CD8+ TIL infiltration demonstrated significantly longer survival than those with low infiltration ( p = 0.03). Among representative clinical cases, a patient with DLL3 (+)/CD8 TILs (−) LCNEC achieved marked tumor shrinkage, whereas a patient with DLL3 (−)/CD8 TILs (−) LCNEC showed no response. Conclusions: DLL3 is frequently expressed in LCNEC and correlates with a poorer prognosis. A majority of LCNEC cases are immunologically characterized as cold tumors lacking CD8+ TILs, which contributes to unfavorable clinical outcomes. Tarlatamab induced a robust antitumor response even in a DLL3 (+) cold tumor. DLL3‐BiTE represents a promising therapeutic strategy for DLL3 (+) LCNEC.
- Open Access
- 28 September 2026
- Published by MDPI AG in Preprints.org
Clinical and Prognostic Significance of Regulator of Chromosome Condensation 1 Expression and Its Complementary Role with Minichromosome Maintenance Protein 2 in Surgically Resected Lung Adenocarcinoma
Background/Objectives: Regulator of chromosome condensation 1 (RCC1) is a nuclear Ran guanine nucleotide exchange factor involved in nucleocytoplasmic transport, DNA replication, and mitotic regulation. This study investigated the clinical and prognostic significance of RCC1 expression and explored whether RCC1 provides complementary prognostic information to minichromosome maintenance protein 2 (MCM2). Methods: A retrospective, single-institution cohort study was conducted on 75 consecutive patients who underwent complete resection for primary lung adenocarcinoma. Tumor-nuclear RCC1 expression was assessed via immunohistochemistry and quantified as a labeling index (LI) from five intratumoral high-power fields. Results: 19 (25.3%) of 75 patients were classified as having RCC1-high tumors, defined as tumors with an exploratory RCC1 threshold of 60%. RCC1-high tumors were more frequently node-positive (pN1–2: 9/19 vs 9/56). RCC1-high expression (≥60%) was associated with shorter recurrence-free survival (RFS) but not overall survival (OS). RCC1-LI was not independently associated with either RFS or OS. Among the 73 patients with data on both markers, the RCC1-negative/MCM2-negative group (n = 27) had the most favorable RFS and OS patterns. Meanwhile, the RCC1-positive/MCM2-positive group (n = 13) exhibited the least favorable RFS pattern. Conclusions: RCC1 expression was associated with nodal involvement. However, it was not an independent prognostic factor for OS or RFS. Based on an exploratory combined-marker analysis, MCM2 may provide the dominant survival-related prognostic signal. However, RCC1 may offer complementary information regarding aggressive tumor behavior and recurrence. These hypothesis-generating findings must be further validated in larger independent cohorts with standardized and reproducible biomarker quantification.
- 28 September 2026
- Published by MDPI AG in Preprints.org
Open AccessClinical and Prognostic Significance of Regulator of Chromosome Condensation 1 Expression and Its Complementary Role with Minichromosome Maintenance Protein 2 in Surgically Resected Lung Adenocarcinoma
Background/Objectives: Regulator of chromosome condensation 1 (RCC1) is a nuclear Ran guanine nucleotide exchange factor involved in nucleocytoplasmic transport, DNA replication, and mitotic regulation. This study investigated the clinical and prognostic significance of RCC1 expression and explored whether RCC1 provides complementary prognostic information to minichromosome maintenance protein 2 (MCM2). Methods: A retrospective, single-institution cohort study was conducted on 75 consecutive patients who underwent complete resection for primary lung adenocarcinoma. Tumor-nuclear RCC1 expression was assessed via immunohistochemistry and quantified as a labeling index (LI) from five intratumoral high-power fields. Results: 19 (25.3%) of 75 patients were classified as having RCC1-high tumors, defined as tumors with an exploratory RCC1 threshold of 60%. RCC1-high tumors were more frequently node-positive (pN1–2: 9/19 vs 9/56). RCC1-high expression (≥60%) was associated with shorter recurrence-free survival (RFS) but not overall survival (OS). RCC1-LI was not independently associated with either RFS or OS. Among the 73 patients with data on both markers, the RCC1-negative/MCM2-negative group (n = 27) had the most favorable RFS and OS patterns. Meanwhile, the RCC1-positive/MCM2-positive group (n = 13) exhibited the least favorable RFS pattern. Conclusions: RCC1 expression was associated with nodal involvement. However, it was not an independent prognostic factor for OS or RFS. Based on an exploratory combined-marker analysis, MCM2 may provide the dominant survival-related prognostic signal. However, RCC1 may offer complementary information regarding aggressive tumor behavior and recurrence. These hypothesis-generating findings must be further validated in larger independent cohorts with standardized and reproducible biomarker quantification.
- Open Access
Surgical Complexity and Perioperative Feasibility Following Neoadjuvant Chemotherapy, Chemoradiotherapy, or Chemoimmunotherapy in Stage II–III Non-Small Cell Lung Cancer: A Retrospective Single-Institution Study
Background: Neoadjuvant chemoimmunotherapy has emerged as a standard option for resectable stage II–III non-small cell lung cancer (NSCLC); however, its impact on surgical feasibility, operative complexity, and perioperative outcomes remains incompletely characterized. We compared surgical feasibility, complexity, and perioperative outcomes across different neoadjuvant strategies. Methods: This single-center retrospective study included patients with stage II–III NSCLC who underwent curative-intent resection following neoadjuvant chemoimmunotherapy (neo-CIT), chemotherapy alone (neo-CT), or chemoradiotherapy (neo-CRT) during the same period. Surgical complexity was assessed using a four-level empirical grading scale. Perioperative outcomes, pathological response, and complications were compared among treatment groups using appropriate nonparametric statistical methods. Results: Twenty-four patients were included in the analysis (neo-CIT, n = 8; neo-CT, n = 12; neo-CRT, n = 4). R0 resection was achieved in 100%, 66.7%, and 75% of patients in the neo-CIT, neo-CT, and neo-CRT groups, respectively. Operative time, estimated blood loss, length of hospital stay, and overall postoperative complication rates did not differ significantly among groups. Thirty-day mortality was 0% in all groups, and 90-day mortality was 12.5% in the neo-CIT group and 0% in the neo-CT and neo-CRT groups. Surgical complexity scores were high across all cohorts and, when analyzed across the entire cohort, were not significantly associated with longer operative time (p = 0.16), greater blood loss (p = 0.83), or pathological response (p = 0.55). Neo-CIT was not associated with increased objective perioperative risk compared with neoadjuvant chemotherapy or chemoradiotherapy. Conclusions: In this single-institution exploratory analysis, neoadjuvant chemoimmunotherapy appeared to be surgically feasible and did not result in an apparent increase in perioperative risk compared with other neoadjuvant strategies. Although surgeons perceived increased operative complexity, objective perioperative risk remained acceptable when procedures were performed by experienced thoracic surgeons. However, given the limited sample size and lack of statistical power, these findings should be interpreted with caution and should not be considered evidence of equivalence.
Open AccessSurgical Complexity and Perioperative Feasibility Following Neoadjuvant Chemotherapy, Chemoradiotherapy, or Chemoimmunotherapy in Stage II–III Non-Small Cell Lung Cancer: A Retrospective Single-Institution Study
Background: Neoadjuvant chemoimmunotherapy has emerged as a standard option for resectable stage II–III non-small cell lung cancer (NSCLC); however, its impact on surgical feasibility, operative complexity, and perioperative outcomes remains incompletely characterized. We compared surgical feasibility, complexity, and perioperative outcomes across different neoadjuvant strategies. Methods: This single-center retrospective study included patients with stage II–III NSCLC who underwent curative-intent resection following neoadjuvant chemoimmunotherapy (neo-CIT), chemotherapy alone (neo-CT), or chemoradiotherapy (neo-CRT) during the same period. Surgical complexity was assessed using a four-level empirical grading scale. Perioperative outcomes, pathological response, and complications were compared among treatment groups using appropriate nonparametric statistical methods. Results: Twenty-four patients were included in the analysis (neo-CIT, n = 8; neo-CT, n = 12; neo-CRT, n = 4). R0 resection was achieved in 100%, 66.7%, and 75% of patients in the neo-CIT, neo-CT, and neo-CRT groups, respectively. Operative time, estimated blood loss, length of hospital stay, and overall postoperative complication rates did not differ significantly among groups. Thirty-day mortality was 0% in all groups, and 90-day mortality was 12.5% in the neo-CIT group and 0% in the neo-CT and neo-CRT groups. Surgical complexity scores were high across all cohorts and, when analyzed across the entire cohort, were not significantly associated with longer operative time (p = 0.16), greater blood loss (p = 0.83), or pathological response (p = 0.55). Neo-CIT was not associated with increased objective perioperative risk compared with neoadjuvant chemotherapy or chemoradiotherapy. Conclusions: In this single-institution exploratory analysis, neoadjuvant chemoimmunotherapy appeared to be surgically feasible and did not result in an apparent increase in perioperative risk compared with other neoadjuvant strategies. Although surgeons perceived increased operative complexity, objective perioperative risk remained acceptable when procedures were performed by experienced thoracic surgeons. However, given the limited sample size and lack of statistical power, these findings should be interpreted with caution and should not be considered evidence of equivalence.
- Open Access
- 5 August 2026
- Published by MDPI AG in Preprints.org
Surgical Complexity and Perioperative Feasibility Following Neoadjuvant Chemotherapy, Chemoradiotherapy, or Chemoimmunotherapy in Stage II–III Non-Small Cell Lung Cancer: A Retrospective Single-Institution Study
Background: Neoadjuvant chemoimmunotherapy is a standard option for resectable stage II–III non-small cell lung cancer (NSCLC); however, its impact on surgical feasibility, operative complexity, and perioperative outcomes remains incompletely characterized. We compared surgical feasibility, complexity, and perioperative outcomes across different neoadjuvant strategies. Methods: This single-center retrospective study included patients with stage II–III NSCLC who underwent curative-intent resection following neoadjuvant chemoimmunotherapy (neo-CIT), chemotherapy alone (neo-CT), or chemoradiotherapy (neo-CRT) during the same period. Surgical complexity was assessed using a four-level empirical grading scale. Perioperative outcomes, pathological response, and complications were compared among treatment groups using appropriate nonparametric statistical methods. Results: Twenty-four patients were included in the analysis (neo-CIT, n = 8; neo-CT, n = 12; neo-CRT, n = 4). R0 resection was achieved in 100%, 83.3%, and 100% of patients in the neo-CIT, neo-CT, and neo-CRT groups, respectively. Operative time, estimated blood loss, length of hospital stay, and overall postoperative complication rates did not differ significantly among groups. Thirty-day mortality was 0% in all groups, and 90-day mortality was 12.5% in the neo-CIT group and 0% in the neo-CT and neo-CRT groups. Surgical complexity scores were high across all cohorts and, when analyzed across the entire cohort, were not significantly associated with longer operative time (P = 0.16), greater blood loss (P = 0.83), or pathological response (P = 0.55). Neo-CIT was not associated with higher conversion rates or increased objective perioperative risk compared with neoadjuvant chemotherapy or chemoradiotherapy. Conclusions: In this single-institution exploratory analysis, neoadjuvant chemoimmunotherapy appeared to be surgically feasible and did not result in an apparent increase in perioperative risk compared with other neoadjuvant strategies. Although surgeons perceived increased operative complexity, objective perioperative risk remained acceptable when procedures were performed by experienced thoracic surgeons. However, considering the limited sample size and lack of statistical power, these findings should be interpreted with caution and should not be considered evidence of equivalence.
- 5 August 2026
- Published by MDPI AG in Preprints.org
Open AccessSurgical Complexity and Perioperative Feasibility Following Neoadjuvant Chemotherapy, Chemoradiotherapy, or Chemoimmunotherapy in Stage II–III Non-Small Cell Lung Cancer: A Retrospective Single-Institution Study
Background: Neoadjuvant chemoimmunotherapy is a standard option for resectable stage II–III non-small cell lung cancer (NSCLC); however, its impact on surgical feasibility, operative complexity, and perioperative outcomes remains incompletely characterized. We compared surgical feasibility, complexity, and perioperative outcomes across different neoadjuvant strategies. Methods: This single-center retrospective study included patients with stage II–III NSCLC who underwent curative-intent resection following neoadjuvant chemoimmunotherapy (neo-CIT), chemotherapy alone (neo-CT), or chemoradiotherapy (neo-CRT) during the same period. Surgical complexity was assessed using a four-level empirical grading scale. Perioperative outcomes, pathological response, and complications were compared among treatment groups using appropriate nonparametric statistical methods. Results: Twenty-four patients were included in the analysis (neo-CIT, n = 8; neo-CT, n = 12; neo-CRT, n = 4). R0 resection was achieved in 100%, 83.3%, and 100% of patients in the neo-CIT, neo-CT, and neo-CRT groups, respectively. Operative time, estimated blood loss, length of hospital stay, and overall postoperative complication rates did not differ significantly among groups. Thirty-day mortality was 0% in all groups, and 90-day mortality was 12.5% in the neo-CIT group and 0% in the neo-CT and neo-CRT groups. Surgical complexity scores were high across all cohorts and, when analyzed across the entire cohort, were not significantly associated with longer operative time (P = 0.16), greater blood loss (P = 0.83), or pathological response (P = 0.55). Neo-CIT was not associated with higher conversion rates or increased objective perioperative risk compared with neoadjuvant chemotherapy or chemoradiotherapy. Conclusions: In this single-institution exploratory analysis, neoadjuvant chemoimmunotherapy appeared to be surgically feasible and did not result in an apparent increase in perioperative risk compared with other neoadjuvant strategies. Although surgeons perceived increased operative complexity, objective perioperative risk remained acceptable when procedures were performed by experienced thoracic surgeons. However, considering the limited sample size and lack of statistical power, these findings should be interpreted with caution and should not be considered evidence of equivalence.
- 3 March 2026
- Published by Wiley in Hepatology Research
- Vol. 56 (6) , 956-965
Characteristic Hepatic Atrophy in Abemaciclib‐Induced Liver Injury: A Comparative Review of Three Cases
Aim: Abemaciclib, a cyclin‐dependent kinase 4/6 inhibitor, is a standard treatment for hormone receptor‐positive and HER2‐negative breast cancer. However, liver dysfunction induced by abemaciclib is a significant clinical issue. Methods: We report three cases of drug induced liver injury caused by abemaciclib with characteristic liver atrophy. Case 1: A woman in her seventies developed acute liver failure 2 months after initiation of letrozole and abemaciclib for breast cancer and bone metastases. A contrast‐enhanced CT (CECT) scan revealed liver atrophy accompanied by Chilaiditi syndrome. Despite steroid pulse therapy, she progressed to coma. Her liver failure improved, but she died due to worsening of the underlying disease. Case 2: A woman in her seventies developed liver dysfunction 2 months after initiation of anastrozole and abemaciclib to prevent recurrence. A CECT scan revealed liver atrophy and Chilaiditi syndrome. After admission, she progressed to acute liver failure and coma, and steroid pulse therapy was initiated. Hepatic encephalopathy improved with conservative treatment, and liver failure resolved with continued steroid administration. Case 3: A woman in her fifties. After breast cancer surgery, tamoxifen and abemaciclib were started as adjuvant therapy. Blood tests revealed liver dysfunction 2 months later. A CECT scan revealed liver atrophy and Chilaiditi syndrome, which improved with liver support therapy alone without progressing to liver failure. Results and Conclusion: This report is the first highlighting the imaging characteristics of rapid‐onset hepatic atrophy associated with abemaciclib‐induced liver injury. These findings may provide useful insights for distinguishing abemaciclib‐induced liver injury from other etiologies.
- 3 March 2026
- Published by Wiley in Hepatology Research
- Vol. 56 (6) , 956-965
Characteristic Hepatic Atrophy in Abemaciclib‐Induced Liver Injury: A Comparative Review of Three Cases
Aim: Abemaciclib, a cyclin‐dependent kinase 4/6 inhibitor, is a standard treatment for hormone receptor‐positive and HER2‐negative breast cancer. However, liver dysfunction induced by abemaciclib is a significant clinical issue. Methods: We report three cases of drug induced liver injury caused by abemaciclib with characteristic liver atrophy. Case 1: A woman in her seventies developed acute liver failure 2 months after initiation of letrozole and abemaciclib for breast cancer and bone metastases. A contrast‐enhanced CT (CECT) scan revealed liver atrophy accompanied by Chilaiditi syndrome. Despite steroid pulse therapy, she progressed to coma. Her liver failure improved, but she died due to worsening of the underlying disease. Case 2: A woman in her seventies developed liver dysfunction 2 months after initiation of anastrozole and abemaciclib to prevent recurrence. A CECT scan revealed liver atrophy and Chilaiditi syndrome. After admission, she progressed to acute liver failure and coma, and steroid pulse therapy was initiated. Hepatic encephalopathy improved with conservative treatment, and liver failure resolved with continued steroid administration. Case 3: A woman in her fifties. After breast cancer surgery, tamoxifen and abemaciclib were started as adjuvant therapy. Blood tests revealed liver dysfunction 2 months later. A CECT scan revealed liver atrophy and Chilaiditi syndrome, which improved with liver support therapy alone without progressing to liver failure. Results and Conclusion: This report is the first highlighting the imaging characteristics of rapid‐onset hepatic atrophy associated with abemaciclib‐induced liver injury. These findings may provide useful insights for distinguishing abemaciclib‐induced liver injury from other etiologies.
- Open Access
- 9 January 2026
- Published by MDPI AG in Journal of Developmental Biology
- Vol. 14 (1) , 5
Influence of Obstructive Uropathy on Cyst Formation and Nephrogenesis: Insights from a Fetal Lamb Model
Obstructive uropathy (OU) during fetal development induces a fetal cystic dysplastic kidney. The mechanisms of cyst formation and the onset of renal dysfunction remain unclear. Determining whether nephrogenic potential persists during fetal life may suggest whether early intervention could preserve renal development. We aimed to evaluate residual nephrogenic activity in fetal cystic dysplastic kidneys using β-catenin and CD10 immunostaining, and to assess whether the site of obstruction influences cystogenesis. After appropriate approval, 20 timed-gestation fetal lambs had OU created at 60 days. Males underwent urethral and urachal ligation (n = 8, 3 lost), and females underwent unilateral ureteric ligation (n = 8, 1 lost). Fetuses were sacrificed at 80 days (n = 6) and 140 days (term, n = 10), comparing kidneys with normal controls of the same gestational age using immunohistochemical staining for β-catenin and CD10. Developing fetal cystic dysplastic kidneys were identified at 80 days. β-catenin staining showed the absence of granular cytoplasmic expression in cystic regions, indicating arrested nephrogenesis. In male models, cysts originated exclusively from proximal tubules. Female models exhibited mixed proximal and distal tubular involvement. CD10 staining confirmed the loss of proximal tubular markers. Renal development remained arrested at term. Cyst formation disrupts renal development early in gestation, which persists until term. Differences in cystogenesis between the models suggest that the site of obstruction influences pathogenic mechanisms.
- 9 January 2026
- Published by MDPI AG in Journal of Developmental Biology
- Vol. 14 (1) , 5
Open AccessInfluence of Obstructive Uropathy on Cyst Formation and Nephrogenesis: Insights from a Fetal Lamb Model
Obstructive uropathy (OU) during fetal development induces a fetal cystic dysplastic kidney. The mechanisms of cyst formation and the onset of renal dysfunction remain unclear. Determining whether nephrogenic potential persists during fetal life may suggest whether early intervention could preserve renal development. We aimed to evaluate residual nephrogenic activity in fetal cystic dysplastic kidneys using β-catenin and CD10 immunostaining, and to assess whether the site of obstruction influences cystogenesis. After appropriate approval, 20 timed-gestation fetal lambs had OU created at 60 days. Males underwent urethral and urachal ligation (n = 8, 3 lost), and females underwent unilateral ureteric ligation (n = 8, 1 lost). Fetuses were sacrificed at 80 days (n = 6) and 140 days (term, n = 10), comparing kidneys with normal controls of the same gestational age using immunohistochemical staining for β-catenin and CD10. Developing fetal cystic dysplastic kidneys were identified at 80 days. β-catenin staining showed the absence of granular cytoplasmic expression in cystic regions, indicating arrested nephrogenesis. In male models, cysts originated exclusively from proximal tubules. Female models exhibited mixed proximal and distal tubular involvement. CD10 staining confirmed the loss of proximal tubular markers. Renal development remained arrested at term. Cyst formation disrupts renal development early in gestation, which persists until term. Differences in cystogenesis between the models suggest that the site of obstruction influences pathogenic mechanisms.
- 14 October 2025
- Published by Wiley in Pathology International
- Vol. 75 (11) , 586-592
A Case of Pancreatic Ductal Adenocarcinoma in PRSS1 ‐Associated Hereditary Pancreatitis in the Absence of High‐Grade PanIN: Suggestive of Chromothripsis‐Like Tumor Evolution
We report a case of pancreatic ductal adenocarcinoma (PDAC) in a 51‐year‐old woman with PRSS1 ‐associated hereditary pancreatitis (HP) and a history of chronic alcohol and tobacco use. Following neoadjuvant chemotherapy, she underwent total pancreatectomy. Histological analysis of the entire pancreas revealed no high‐grade PanINs and scattered low‐grade PanINs, with and without KRAS mutations, indicating molecular heterogeneity. Genomic profiling identified multiple driver alterations, comprising both clonal and subclonal events, including mutations in KRAS, CDKN2A/B, SMAD4, ATRX, MSH3 , and the TERT promoter. Immunohistochemistry showed strong nuclear p53 overexpression despite the absence of TP53 mutation, suggesting a chromosomal instability phenotype. These findings support the hypothesis of a chromothripsis‐like catastrophic genomic event contributing to rapid oncogenesis, bypassing the conventional PanIN sequence. The background of chronic inflammation, advanced lipomatous atrophy, and environmental exposures may have facilitated this transformation. This case underscores the need to consider alternative, nonlinear pathways of PDAC development in genetically predisposed individuals and highlights the potential utility of molecular surveillance for early detection and risk stratification.
- 14 October 2025
- Published by Wiley in Pathology International
- Vol. 75 (11) , 586-592
A Case of Pancreatic Ductal Adenocarcinoma in PRSS1 ‐Associated Hereditary Pancreatitis in the Absence of High‐Grade PanIN: Suggestive of Chromothripsis‐Like Tumor Evolution
We report a case of pancreatic ductal adenocarcinoma (PDAC) in a 51‐year‐old woman with PRSS1 ‐associated hereditary pancreatitis (HP) and a history of chronic alcohol and tobacco use. Following neoadjuvant chemotherapy, she underwent total pancreatectomy. Histological analysis of the entire pancreas revealed no high‐grade PanINs and scattered low‐grade PanINs, with and without KRAS mutations, indicating molecular heterogeneity. Genomic profiling identified multiple driver alterations, comprising both clonal and subclonal events, including mutations in KRAS, CDKN2A/B, SMAD4, ATRX, MSH3 , and the TERT promoter. Immunohistochemistry showed strong nuclear p53 overexpression despite the absence of TP53 mutation, suggesting a chromosomal instability phenotype. These findings support the hypothesis of a chromothripsis‐like catastrophic genomic event contributing to rapid oncogenesis, bypassing the conventional PanIN sequence. The background of chronic inflammation, advanced lipomatous atrophy, and environmental exposures may have facilitated this transformation. This case underscores the need to consider alternative, nonlinear pathways of PDAC development in genetically predisposed individuals and highlights the potential utility of molecular surveillance for early detection and risk stratification.
- 23 August 2025
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 51 (8) , e70049
Validation of the 2023 FIGO staging system and its concordance with the JSGO guidelines in endometrial cancer: A multi‐institutional retrospective study in Japan
Aim: To validate the prognostic accuracy of the 2023 FIGO staging system and assess its alignment with the Japan Society of Gynecologic Oncology (JSGO) guidelines for endometrial cancer treatment. Methods: This retrospective cohort study included 1207 patients with endometrial cancer treated at four academic hospitals in Kanagawa, Japan, between 2018 and 2022. Patients were reclassified according to the FIGO 2023 system and the JSGO recurrence risk categories. Primary endpoints included stage migration, recurrence risk (RR), overall survival (OS), and concordance between the two classification systems. Results: Under FIGO 2023, the stage distribution was: I, 741 (61.4%); II, 203 (16.8%); III, 149 (12.3%); and IV, 114 (9.4%), with stage migration observed in 36.3% of cases. The FIGO 2023 system provided clearer stratification of 3‐year RR than FIGO 2009, with the RR gap widening from 80.0% to 90.1%. Sixteen patients (3.5%) with stage IA3 were classified as high risk by JSGO criteria, while 14.4% of patients considered high risk by JSGO were downstaged under FIGO 2023. Additionally, 46 patients (19.6%) with FIGO stage IA were reclassified as intermediate risk owing to focal lymphovascular space invasion (LVSI). Substantial LVSI was significantly associated with recurrence and poor prognosis (3‐year OS rates: none 94.3%, focal 89.9%, and substantial 40.7%; p < 0.05). Molecular testing was limited: p53 in 30.2%, MSI in 5.9%, and POLE was not available. Conclusions: FIGO 2023 improves prognostic precision. Incorporating LVSI extent and molecular data may refine JSGO classifications and support more individualized adjuvant therapy strategies.
- 23 August 2025
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 51 (8) , e70049
Validation of the 2023 FIGO staging system and its concordance with the JSGO guidelines in endometrial cancer: A multi‐institutional retrospective study in Japan
Aim: To validate the prognostic accuracy of the 2023 FIGO staging system and assess its alignment with the Japan Society of Gynecologic Oncology (JSGO) guidelines for endometrial cancer treatment. Methods: This retrospective cohort study included 1207 patients with endometrial cancer treated at four academic hospitals in Kanagawa, Japan, between 2018 and 2022. Patients were reclassified according to the FIGO 2023 system and the JSGO recurrence risk categories. Primary endpoints included stage migration, recurrence risk (RR), overall survival (OS), and concordance between the two classification systems. Results: Under FIGO 2023, the stage distribution was: I, 741 (61.4%); II, 203 (16.8%); III, 149 (12.3%); and IV, 114 (9.4%), with stage migration observed in 36.3% of cases. The FIGO 2023 system provided clearer stratification of 3‐year RR than FIGO 2009, with the RR gap widening from 80.0% to 90.1%. Sixteen patients (3.5%) with stage IA3 were classified as high risk by JSGO criteria, while 14.4% of patients considered high risk by JSGO were downstaged under FIGO 2023. Additionally, 46 patients (19.6%) with FIGO stage IA were reclassified as intermediate risk owing to focal lymphovascular space invasion (LVSI). Substantial LVSI was significantly associated with recurrence and poor prognosis (3‐year OS rates: none 94.3%, focal 89.9%, and substantial 40.7%; p < 0.05). Molecular testing was limited: p53 in 30.2%, MSI in 5.9%, and POLE was not available. Conclusions: FIGO 2023 improves prognostic precision. Incorporating LVSI extent and molecular data may refine JSGO classifications and support more individualized adjuvant therapy strategies.
- Open Access
- 18 November 2023
- Published by Springer Nature in Virchows Archiv
- Vol. 483 (6) , 809-819
Clinicopathological differences in focal segmental glomerulosclerosis depending on the accompanying pathophysiological conditions in renal allografts
Primary focal segmental glomerulosclerosis (FSGS) is thought to be caused by circulating factors leading to podocytopathy, whereas segmental sclerotic lesions (FSGS lesions) have several causes. We studied the clinicopathological differences of FSGS-lesions in 258 cases of FSGS in renal allografts, depending on the following accompanying pathophysiology: recurrence of primary FSGS, calcineurin inhibitor (CNI)-induced arteriolopathy, antibody-mediated rejection (ABMR), and other conditions. All cases were categorized with the Columbia classification. Recurrent FSGS developed the earliest after transplantation and showed the highest percentage of the collapsing (COL) variant in which collapse of the glomerular capillaries with epithelial hypertrophy was apparent. FSGS accompanying CNI-induced arteriolopathy predominantly developed the not otherwise specified (NOS) variant, showing severe ultrastructural endothelial injury. On the contrary, approximately 7% of the cases showed the COL variant, presenting glomerular endothelial damage such as double contours of glomerular basement membrane and endothelial cell swelling as well as epithelial cell proliferation. FSGS with ABMR had the highest creatinine levels and cellular variant percentage, with marked inflammation and ultrastructural endothelial injury. Approximately two-thirds of the cases without ABMR, CNI-induced arteriopathy, or recurrent FSGS had other coexisting conditions such as glomerulonephritis, T cell-mediated rejection, and reflux nephropathy with progressive tubulointerstitial fibrosis. Most of these cases were of the NOS variant. The clinicopathologic features of post-transplant FSGS differed depending on the associated conditions, and endothelial injury was apparent especially in cases of CNI-induced arteriolopathy and ABMR. Precise observation of FSGS lesions may facilitate the diagnosis and clinical management of FSGS during renal transplantation.
- 18 November 2023
- Published by Springer Nature in Virchows Archiv
- Vol. 483 (6) , 809-819
Open AccessClinicopathological differences in focal segmental glomerulosclerosis depending on the accompanying pathophysiological conditions in renal allografts
Primary focal segmental glomerulosclerosis (FSGS) is thought to be caused by circulating factors leading to podocytopathy, whereas segmental sclerotic lesions (FSGS lesions) have several causes. We studied the clinicopathological differences of FSGS-lesions in 258 cases of FSGS in renal allografts, depending on the following accompanying pathophysiology: recurrence of primary FSGS, calcineurin inhibitor (CNI)-induced arteriolopathy, antibody-mediated rejection (ABMR), and other conditions. All cases were categorized with the Columbia classification. Recurrent FSGS developed the earliest after transplantation and showed the highest percentage of the collapsing (COL) variant in which collapse of the glomerular capillaries with epithelial hypertrophy was apparent. FSGS accompanying CNI-induced arteriolopathy predominantly developed the not otherwise specified (NOS) variant, showing severe ultrastructural endothelial injury. On the contrary, approximately 7% of the cases showed the COL variant, presenting glomerular endothelial damage such as double contours of glomerular basement membrane and endothelial cell swelling as well as epithelial cell proliferation. FSGS with ABMR had the highest creatinine levels and cellular variant percentage, with marked inflammation and ultrastructural endothelial injury. Approximately two-thirds of the cases without ABMR, CNI-induced arteriopathy, or recurrent FSGS had other coexisting conditions such as glomerulonephritis, T cell-mediated rejection, and reflux nephropathy with progressive tubulointerstitial fibrosis. Most of these cases were of the NOS variant. The clinicopathologic features of post-transplant FSGS differed depending on the associated conditions, and endothelial injury was apparent especially in cases of CNI-induced arteriolopathy and ABMR. Precise observation of FSGS lesions may facilitate the diagnosis and clinical management of FSGS during renal transplantation.
- Open Access
- 18 September 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (18) , 2977
Ultrasound Doppler Findings in Fetal Vascular Malperfusion Due to Umbilical Cord Abnormalities: A Pilot Case Predictive for Cerebral Palsy
Fetal Vascular Malperfusion (FVM), a pathologic condition in the feto-placental circulation, is a chronic vaso-occlusive disorder in the umbilical venous blood flow. Microthrombi are caused by the umbilical cord’s blood flow deficiency in a congested umbilical vein, which also causes microvascular damage to fetal organs, especially the brain, resulting in cerebral palsy. Thrombo-occlusive events also adversely affect the upstream chorionic or stem vessels in the placenta, resulting in fetal growth restriction and fetal hypoxia. An umbilical cord structural anomaly or multiple entanglements may involve FVM. In the present report, we demonstrate a case of FVM caused by multiple umbilical cord abnormalities obtained from antenatal ultrasound Doppler findings, and we also discuss FVM, which is chronically associated with CP, comparing the ultrasonographic findings to the pathologic findings.
- 18 September 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (18) , 2977
Open AccessUltrasound Doppler Findings in Fetal Vascular Malperfusion Due to Umbilical Cord Abnormalities: A Pilot Case Predictive for Cerebral Palsy
Fetal Vascular Malperfusion (FVM), a pathologic condition in the feto-placental circulation, is a chronic vaso-occlusive disorder in the umbilical venous blood flow. Microthrombi are caused by the umbilical cord’s blood flow deficiency in a congested umbilical vein, which also causes microvascular damage to fetal organs, especially the brain, resulting in cerebral palsy. Thrombo-occlusive events also adversely affect the upstream chorionic or stem vessels in the placenta, resulting in fetal growth restriction and fetal hypoxia. An umbilical cord structural anomaly or multiple entanglements may involve FVM. In the present report, we demonstrate a case of FVM caused by multiple umbilical cord abnormalities obtained from antenatal ultrasound Doppler findings, and we also discuss FVM, which is chronically associated with CP, comparing the ultrasonographic findings to the pathologic findings.